Abstract
Importance Blood donors are at increased risk for iron deficiency. Current hemoglobin (Hb) monitoring policies are inadequate and iron management strategies are warranted.
Objective To determine the effects of ferritin-guided donation intervals for whole blood donors on Hb and ferritin levels, Hb deferral, iron deficiency (ferritin < 15 ng/mL) prevalence, donor return, iron deficiency-related symptoms, and the blood supply.
Design, setting and participants Between November 2017 and November 2019 a ferritin-guided donation interval policy was implemented and evaluated through a stepped-wedge cluster-randomized controlled trial in all blood collection centers in the Netherlands. During the study period, 412,888 donors visited the blood bank.
Interventions Ferritin was measured in new donors and at every 5th whole blood donation. Subsequent donation intervals were extended to six months if ferritin is 15 ≤ 30 ng/mL and to twelve months if ferritin is <15 ng/mL.
Main outcomes and Measures Primary outcomes are ferritin and Hb levels, iron deficiency, Hb deferral, and donor return. Secondary outcomes are self-reported iron deficiency-related symptoms. Yearly donor and donation statistics were used to assess the impact on the blood supply.
Results We measured 36,099 donors, median age 43 years and 52% female, making 37,621 donations during the study period. Ferritin-guided donation intervals were associated with increased log-transformed ferritin levels at all time points in the trial, up to 0.24 log10 ng/mL as compared to baseline (95% CI 0.22 – 0.27, p <0.001). Hb increased as well, up to 0.37 g/dL (95% CI 0.31 – 0.43, p <0.001). Decreased odds of 85% (95% CI OR 0.10 – 0.21, p <0.001) for iron deficiency and 77% (95% CI OR 0.11 – 0.41, p <0.001) for Hb deferral were reported compared to baseline. Odds of donor return decreased over the course of the trial, with as much as 40% (95% CI OR 0. 51 – 0.67, p <0.001). We found no evidence for improved self-reported iron deficiency-related symptoms after implementation of the new policy. More invitations had to be sent to donors to obtain one donation and the average donation frequency per year decreased.
Conclusion and Relevance Ferritin-guided donation intervals were significantly associated with increasing overall Hb and ferritin levels, thereby decreasing the prevalence of iron deficiency and Hb deferrals in whole blood donors. Ferritin-guided donation intervals seem beneficial for Hb levels and iron maintenance, but additional efforts are required to retain donors and to remedy self-reported iron deficiency-related symptoms.
Trial Registration This trial has been registered in the Dutch trial registry (NTR6738) on September 29th, 2017 (https://trialsearch.who.int/Trial2.aspx?TrialID=NTR6738).
Question Are ferritin-guided donation intervals effective in diminishing iron deficiency and low hemoglobin in whole blood donors?
Findings In this stepped-wedge cluster randomized trial with 412,888 donors and 1,643,700 donations, ferritin-guided donation intervals were associated with a significant improvement in hemoglobin and ferritin levels and decreased donor return rates. Data did not suggest improved self-reported health outcomes.
Meaning Ferritin-guided donation intervals, in addition to hemoglobin monitoring, as part of the donor iron management strategy of blood establishments effectively reduce the prevalence of iron deficiency and anemia in whole blood donors, but additional efforts to retain donors are required.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NTR6738
Clinical Protocols
https://pubmed.ncbi.nlm.nih.gov/32998766/
Funding Statement
The current project is supported by the Product and Process Development Cellular Products Grant (PPOC18-15) granted to K. van den Hurk by the Research Programming Committee, Sanquin, Amsterdam, The Netherlands.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Board of Directors, the Medical Advisory Council and Ethics Advisory Council of Sanquin Blood Supply Foundation gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
a.meulenbeld{at}sanquin.nl, s.ramondt{at}vu.nl, m.sweegers{at}nki.nl, f.quee{at}sanquin.nl, f.prinsze{at}sanquin.nl, e.hoogendijk{at}amsterdamumc.nl, dorine.swinkels{at}radboudumc.nl, k.vandenhurk{at}sanquin.nl
Broadened the scope by adding an additional outcome and adjusted methods, results and discussion accordingly. As a result, replaced Table 2 with new outcomes. Updated figure 3 and the supplemental tables.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
